Released Mar 6, 2025, after the close
10-K filed Mar 6, 2025, 65 days after period end · 0001628280-25-010933
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.86M$2.86M derived−50.5% vs Q4 2023−63.4% vs Q3 2024
Net Income-$19.50M-$19.50M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$24,005,000N/M
Operating Cash Flowderived-$24,519,000N/M
Free Cash Flowderived-$24,998,000N/M
Margins · derived
Operating margin-840.5%−399.2 pt vs Q4 2023
Net margin-682.9%−265.0 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.86M | $5.77M | $4.18M | $713.00K |
| Net Income | -$19.50M | -$24.11M | -$28.89M | -$29.14M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR